Miguel Brito

507 total citations
9 papers, 347 citations indexed

About

Miguel Brito is a scholar working on Radiology, Nuclear Medicine and Imaging, Ophthalmology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Miguel Brito has authored 9 papers receiving a total of 347 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Radiology, Nuclear Medicine and Imaging, 7 papers in Ophthalmology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Miguel Brito's work include Retinal Diseases and Treatments (7 papers), Retinal Imaging and Analysis (5 papers) and Retinal and Macular Surgery (3 papers). Miguel Brito is often cited by papers focused on Retinal Diseases and Treatments (7 papers), Retinal Imaging and Analysis (5 papers) and Retinal and Macular Surgery (3 papers). Miguel Brito collaborates with scholars based in Brazil, Venezuela and Argentina. Miguel Brito's co-authors include Arturo Alezzandrini, Maurício Maia, Lihteh Wu, J. Fernando Arévalo, M. Díaz-Llopis, J. García Sánchez, Patricia Udaondo, Francisco J. Rodríguez, Andrés F. Lasave and Silvio Lujan and has published in prestigious journals such as Ophthalmology, The American Journal of Human Genetics and Retina.

In The Last Decade

Miguel Brito

9 papers receiving 331 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Miguel Brito Brazil	8	223	215	66	47	38	9	347
Mamoru Ogawa Japan	12	76 0.3×	112 0.5×	14 0.2×	67 1.4×	92 2.4×	24	301
Ricky W.K. Law China	10	248 1.1×	284 1.3×	2 0.0×	18 0.4×	88 2.3×	16	459
James P. Kersey United Kingdom	9	342 1.5×	186 0.9×		60 1.3×	56 1.5×	13	493
Mingui Kong South Korea	12	239 1.1×	224 1.0×		28 0.6×	22 0.6×	41	325
Nilay Yüksel Türkiye	10	220 1.0×	164 0.8×		32 0.7×	31 0.8×	43	365
Daniel Gologorsky United States	8	174 0.8×	94 0.4×	1 0.0×	52 1.1×	53 1.4×	21	269
Marc Figueras‐Roca Spain	14	294 1.3×	201 0.9×		25 0.5×	65 1.7×	44	400
Claus Zehetner Austria	11	403 1.8×	314 1.5×		23 0.5×	83 2.2×	44	476
John Thygesen Denmark	10	336 1.5×	191 0.9×		57 1.2×	17 0.4×	19	431
Pierre Gascon France	11	271 1.2×	97 0.5×		35 0.7×	37 1.0×	45	330

Countries citing papers authored by Miguel Brito

Since Specialization

Citations

This map shows the geographic impact of Miguel Brito's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miguel Brito with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miguel Brito more than expected).

Fields of papers citing papers by Miguel Brito

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miguel Brito. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miguel Brito. The network helps show where Miguel Brito may publish in the future.

Co-authorship network of co-authors of Miguel Brito

This figure shows the co-authorship network connecting the top 25 collaborators of Miguel Brito. A scholar is included among the top collaborators of Miguel Brito based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miguel Brito. Miguel Brito is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Brito, Miguel, et al.. (2018). Analysis of the Recurrence of Plus Disease after Intravitreal Ranibizumab as a Primary Monotherapy for Severe Retinopathy of Prematurity. Ophthalmology Retina. 2(8). 858–863. 13 indexed citations

2.

Arévalo, J. Fernando, Andrés F. Lasave, Lihteh Wu, et al.. (2016). INTRAVITREAL BEVACIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY. Retina. 37(2). 334–343. 38 indexed citations

3.

Arévalo, J. Fernando, Andrés F. Lasave, Lihteh Wu, et al.. (2016). Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy: Results from the Pan-American Collaborative Retina Study Group (PACORES) at 24 Months of Follow-up. 57(12). 1 indexed citations

4.

Brito, Miguel, et al.. (2015). Intravitreal ranibizumab as a primary or a combined treatment for severe retinopathy of prematurity. Clinical ophthalmology. 9. 2027–2027. 23 indexed citations

5.

Arévalo, J. Fernando, J. García Sánchez, Andrés F. Lasave, et al.. (2011). Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture. Journal of Ophthalmology. 2011. 1–13. 40 indexed citations

6.

Arévalo, J. Fernando, J. García Sánchez, Andrés F. Lasave, et al.. (2010). Intravitreal Bevacizumab (Avastin®) for Diabetic Retinopathy at 24-months: The 2008 Juan Verdaguer-Planas Lecture. Current Diabetes Reviews. 6(5). 313–322. 23 indexed citations

7.

Arévalo, J. Fernando, J. García Sánchez, Lihteh Wu, et al.. (2010). Intravitreal Bevacizumab for Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration at Twenty-four Months: The Pan-American Collaborative Retina Study. Ophthalmology. 117(10). 1974–1981.e1. 29 indexed citations

8.

Arévalo, J. Fernando, J. García Sánchez, Lihteh Wu, et al.. (2009). Primary Intravitreal Bevacizumab for Diffuse Diabetic Macular Edema. Ophthalmology. 116(8). 1488–1497.e1. 96 indexed citations

9.

Liu, Jianjun, Suh‐Hang Hank Juo, P. Holopainen, et al.. (2002). Genomewide Linkage Analysis of Celiac Disease in Finnish Families. The American Journal of Human Genetics. 70(1). 51–59. 84 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact